2. Academic Validation
  3. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin

MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin

  • Oncotarget. 2016 Apr 26;7(17):23300-11. doi: 10.18632/oncotarget.8188.
Yihui Wen 1 2,  Hua Li 3,  Yan Zeng 3,  Weiping Wen 1,  Kelsey P Pendleton 2,  Vivian W Y Lui 4,  Ann Marie Egloff 2 5,  Jennifer R Grandis 3 6
Affiliations

Affiliations

  • 1 Department of Otolaryngology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.
  • 2 Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • 3 Department of Otolaryngology Head and Neck Surgery, University of California at San Francisco, San Francisco, California, USA.
  • 4 Department of Pharmacology and Pharmacy, School of Biomedical Sciences, Li-Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
  • 5 Departments of Molecular and Cell Biology and Otolaryngology, Boston University, Boston, Massachusetts, USA.
  • 6 Clinical and Translational Science Institute, University of California at San Francisco, San Francisco, California, USA.
PMID: 27004400 DOI: 10.18632/oncotarget.8188
Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have not been effective in unselected head and neck squamous cell carcinoma (HNSCC) populations. We previously reported an exceptional response to a brief course of erlotinib in a patient with advanced HNSCC whose tumor harbored a MAPK1E322K somatic mutation. MAPK1E322Kwas associated with increased p-EGFR, increased EGFR downstream signaling and increased sensitivity to erlotinib. In this study, we investigated the mechanism of MAPK1E322K-mediated EGFR activation in the context of erlotinib sensitivity. We demonstrated increased AREG secretion in HNSCC cell lines harboring endogenous or exogenous MAPK1E322K compared to wild type MAPK1. We found inhibition or knockdown of MAPK1 with siRNA resulted in reduced secretion of AREG and decreased sensitivity to erlotinib in the setting of MAPK1E322K. MAPK1E322K was associated with increased AREG secretion leading to an autocrine feedback loop involving AREG, EGFR and downstream signaling. Knockdown of AREG in HNSCC cells harboring MAPK1E322K abrogated EGFR signaling and decreased sensitivity to erlotinib in vitro and in vivo. These cumulative findings implicate increased AREG secretion and EGFR activation as contributing to increased erlotinib sensitivity in MAPK1E322K HNSCC.

Keywords

ERK2; MAPK1; amphiregulin; head and neck cancer; mutation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-14178
    99.17%, ERK抑制剂
    ERK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z